Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 58.69 USD -2.09% Market Closed
Market Cap: 119B USD
Have any thoughts about
Bristol-Myers Squibb Co?
Write Note

Net Margin
Bristol-Myers Squibb Co

-15.3%
Current
7%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-15.3%
=
Net Income
-7.3B
/
Revenue
47.4B

Net Margin Across Competitors

Country US
Market Cap 119B USD
Net Margin
-15%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 772.5B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.5T DKK
Net Margin
35%
Country US
Market Cap 366.8B USD
Net Margin
17%
Country US
Market Cap 257.9B USD
Net Margin
19%
Country CH
Market Cap 202.9B CHF
Net Margin
20%
Country UK
Market Cap 167.3B GBP
Net Margin
13%
Country CH
Market Cap 182B CHF
Net Margin
35%
Country IE
Market Cap 145.9B USD
Net Margin
-126%
No Stocks Found

Bristol-Myers Squibb Co
Glance View

Market Cap
119B USD
Industry
Pharmaceuticals
Economic Moat
None

Bristol-Myers Squibb Co. (BMS) is a global biopharmaceutical company renowned for its innovative approach to discovering and developing transformative medicines. Founded over 160 years ago, BMS has built a robust portfolio that includes therapies across oncology, immunology, cardiovascular disease, and infectious diseases, focusing on addressing unmet medical needs. The company is celebrated for its substantial investments in research and development, which have led to groundbreaking treatments like Opdivo and Eliquis. These products have not only propelled revenue growth but also established BMS as a key player in the life sciences sector, showcasing its commitment to advancing the health and well-being of patients around the world. For investors, BMS presents a compelling opportunity rooted in a strong pipeline and strategic partnerships. The company has navigated recent challenges, including patent expirations, by fostering innovation and expanding its therapeutic offerings through mergers and acquisitions. In the ever-evolving healthcare landscape, BMS aims to leverage its scientific expertise and market presence to drive sustainable growth. With a focus on maintaining a balanced portfolio and a disciplined approach to capital allocation, Bristol-Myers Squibb stands out as a resilient entity poised to deliver long-term value, supported by a robust pipeline expected to bring additional blockbuster products to market in the coming years.

BMY Intrinsic Value
73.25 USD
Undervaluation 20%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-15.3%
=
Net Income
-7.3B
/
Revenue
47.4B
What is the Net Margin of Bristol-Myers Squibb Co?

Based on Bristol-Myers Squibb Co's most recent financial statements, the company has Net Margin of -15.3%.